Evidence map›Paper›PMID 38242576›Full record

ArticleBJS open2024

Prognostic impact of extramural venous invasion detected by contrast-enhanced CT colonography in colon cancer.

Takeharu Kato, Shunsuke Tsukamoto, Mototaka Miyake, Yozo Kudose, Yasuyuki Takamizawa, Konosuke Moritani, Hiroyuki Daiko, Yukihide Kanemitsu

Open access · goldAbstract read
In one paragraph

Article in BJS open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Development of a nomogram for predicting extramural venous invasion in colon cancer using spectral CT multiparameter imaging.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Takeharu KatoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.ORCID 0009-0006-0705-816X
Shunsuke TsukamotoDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-5143-6312
Mototaka MiyakeDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Yozo KudoseDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yasuyuki TakamizawaDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.
Konosuke MoritaniDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0001-6959-7210
Hiroyuki DaikoCourse of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0002-9562-2966
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-3366-3826
Tokyo National Hospital · JPJuntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of computed tomography (CT)-detected extramural venous invasion on the recurrence of colon cancer is not fully understood. The aim of this study was to investigate the clinical significance of extramural venous invasion diagnosed before surgery by contrast-enhanced CT colonography using three-dimensional multiplanar reconstruction images.

methodsPatients with colon cancer staged greater than or equal to T2 and/or stage I-III who underwent contrast-enhanced CT colonography between 2013 and 2018 at the National Cancer Center Hospital in Japan were retrospectively investigated for CT-detected extramural venous invasion. Inter-observer agreement for the detection of CT-detected extramural venous invasion was evaluated and Kaplan-Meier survival curves were plotted for recurrence-free survival using CT-TNM staging and CT-detected extramural venous invasion. Preoperative clinical variables were analysed using Cox regression for recurrence-free survival.

resultsOut of 922 eligible patients, 544 cases were analysed (50 (9.2 per cent) were diagnosed as positive for CT-detected extramural venous invasion and 494 (90.8 per cent) were diagnosed as negative for CT-detected extramural venous invasion). The inter-observer agreement for CT-detected extramural venous invasion had a κ coefficient of 0.830. The group positive for CT-detected extramural venous invasion had a median follow-up of 62.1 months, whereas the group negative for CT-detected extramural venous invasion had a median follow-up of 60.7 months. When CT-TNM stage was stratified according to CT-detected extramural venous invasion status, CT-T3 N(-)extramural venous invasion(+) had a poor prognosis compared with CT-T3 N(-)extramural venous invasion(-) and CT-stage I (5-year recurrence-free survival of 50.6 versus 89.3 and 90.1 per cent respectively; P < 0.001). In CT-stage III, the group positive for CT-detected extramural venous invasion also had a poor prognosis compared with the group negative for CT-detected extramural venous invasion (5-year recurrence-free survival of 52.0 versus 78.5 per cent respectively; P = 0.003). Multivariable analysis revealed that recurrence was associated with CT-T4 (HR 3.10, 95 per cent c.i. 1.85 to 5.20; P < 0.001) and CT-detected extramural venous invasion (HR 3.08, 95 per cent c.i. 1.90 to 5.00; P < 0.001).

conclusionCT-detected extramural venous invasion was found to be an independent predictor of recurrence and could be used in combination with preoperative TNM staging to identify patients at high risk of recurrence.

Indexed as

Colonic NeoplasmsColonography, Computed TomographicHumansNeoplasm StagingPrognosisRetrospective Studies

Identifiers

PMID38242576
PMCPMC10799315
OpenAlexW4391053636

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.